PT - JOURNAL ARTICLE AU - Liu, Yang AU - Gong, Wenfeng AU - Clifford, Samuel AU - Sundaram, Maria E. AU - , AU - Jit, Mark AU - Flasche, Stefan AU - Klepac, Petra TI - A Modelling Study for Designing a Multi-layered Surveillance Approach to Detect the Potential Resurgence of SARS-CoV-2 AID - 10.1101/2020.06.27.20141440 DP - 2020 Jan 01 TA - medRxiv PG - 2020.06.27.20141440 4099 - http://medrxiv.org/content/early/2020/06/29/2020.06.27.20141440.short 4100 - http://medrxiv.org/content/early/2020/06/29/2020.06.27.20141440.full AB - Background Countries achieving control of COVID-19 after an initial outbreak will continue to face the risk of SARS-CoV-2 resurgence. This study explores surveillance strategies for COVID-19 containment based on polymerase chain reaction tests.Methods Using a dynamic SEIR-type model to simulate the initial dynamics of a COVID-19 introduction, we investigate COVID-19 surveillance strategies among healthcare workers, hospital patients, and community members. We estimate surveillance sensitivity as the probability of COVID-19 detection using a hypergeometric sampling process. We identify test allocation strategies that maximise the probability of COVID-19 detection across different testing capacities. We use Beijing, China as a case study.Findings Surveillance subgroups are more sensitive in detecting COVID-19 transmission when they are defined by more COVID-19 specific symptoms. In this study, fever clinics have the highest surveillance sensitivity, followed by respiratory departments. With a daily testing rate of 0.07/1000 residents, via exclusively testing at fever clinic and respiratory departments, there would have been 598 [95% eCI: 35, 2154] and 1373 [95% eCI: 47, 5230] cases in the population by the time of first case detection, respectively. Outbreak detection can occur earlier by including non-syndromic subgroups, such as younger adults in the community, as more testing capacity becomes available.Interpretation A multi-layer approach that considers both the surveillance sensitivity and administrative constraints can help identify the optimal allocation of testing resources and thus inform COVID-19 surveillance strategies.Funding Bill & Melinda Gates Foundation, National Institute of Health Research (UK), National Institute of Health (US), the Royal Society, and Wellcome Trust.Competing Interest StatementThe authors have declared no competing interest.Funding StatementYL and MJ are funded by the National Institute of Health Research (UK)(16/137/109), the Bill & Melinda Gates Foundation (INV-003174), and the European Commission (101003688). PK is funded by the Royal Society (UK)(RP\EA\180004), the Bill & Melinda Gates Foundation (INV-003174), and the European Commission (101003688). SF and SC are funded through a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (Grant Number 208812/Z/17/Z). MES is funded by the National Institute of Allergy and Infectious Diseases (US)(T32AI074492). This research was partly funded by the National Institute for Health Research (NIHR) (16/137/109) using UK aid from the UK Government to support global health research. The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the UK Department of Health and Social Care. This research is partly funded by the Bill & Melinda Gates Foundation (INV-003174). The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Bill & Melinda Gates Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:London School of Hygiene and Tropical MedicineAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis study is based on data in the published literature or publicly available online databases.